Global Rank
#20345
Country Rank
#256
Market Cap
$205.77 M
Price
$4.13
Change (%)
5.42%
Volume
237,114
Genfit S.A.'s latest marketcap:
$205.77 M
As of 08/14/2025, Genfit S.A.'s market capitalization has reached $205.77 M. According to our data, Genfit S.A. is the 20345th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | $205.77 M |
| Revenue (ttm) | $82.57 M |
| Net Income (ttm) | $1.76 M |
| Shares Out | 49.8 M |
| EPS (ttm) | $0.04 |
| Forward PE | 0.00 |
| Ex-Dividend Date | n/a |
| Earnings Date | 09/22/2025 |
Market Cap Chart
Data Updated: 08/14/2025
Genfit S.A.'s yearly market capitalization.
Genfit S.A. has seen its market value drop from €902.73 M to €176.18 M since 2014, representing a total decrease of 80.48% and an annual compound decline rate (CAGR) of 14.26%.
| Date | Market Cap(€) | Market Cap(USD) | Change (%) | Global Rank |
|---|---|---|---|---|
| 08/14/2025 | €176.18 M | $205.77 M | -5.76% | 20345 |
| 12/31/2024 | €176.27 M | $182.48 M | 0.17% | 19554 |
| 12/29/2023 | €175.98 M | $194.24 M | -10.69% | 18990 |
| 12/30/2022 | €197.03 M | $210.87 M | -8.19% | 17720 |
| 12/31/2021 | €214.62 M | $243.93 M | 38.52% | 17685 |
| 12/31/2020 | €154.93 M | $189.23 M | -77.37% | 17068 |
| 12/31/2019 | €684.56 M | $767.59 M | 26.63% | 7985 |
| 12/31/2018 | €540.58 M | $619.83 M | -27.48% | 8041 |
| 12/29/2017 | €745.39 M | $894.02 M | 13.85% | 7650 |
| 12/30/2016 | €654.7 M | $688.48 M | -16.05% | 8179 |
Company Profile
About Genfit S.A.
Genfit S.A. is a late-stage biopharmaceutical company focused on discovering and developing innovative drug candidates and diagnostic solutions for metabolic and liver-related diseases.
Key Developments
- Elafibranor – Currently in Phase III clinical trials for treating primary biliary cholangitis (PBC).
- NIS4 Technology – A diagnostic tool for nonalcoholic steatohepatitis (NASH) and fibrosis.
- VS-01 – A treatment under development for Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD).
- GNS561 – In Phase 1b/2a trials for cholangiocarcinoma (CCA).
- VS-01-ACLF & Nitazoxanide (NTZ) – In Phase 1 trials for acute-on-chronic liver failure.
- VS-02-HE – In preclinical trials for reducing hyperammonemia and stabilizing blood ammonia levels.
- SRT-015 – An ASK1 inhibitor targeting cellular apoptosis, inflammation, and fibrosis.
Strategic Partnerships
- Labcorp – Licensing agreement for the commercialization of NASHnext, a blood-based molecular diagnostic test.
- Genoscience Pharma – Collaboration to develop and commercialize GNS561 for CCA.
Company Background
Founded in 1999, Genfit S.A. is headquartered in Loos, France.
Frequently Asked Questions
-
What is Genfit S.A.'s (EPA-GNFT) current market cap?As of 08/14/2025, Genfit S.A. (including the parent company, if applicable) has an estimated market capitalization of $205.77 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Genfit S.A. (EPA-GNFT) rank globally by market cap?Genfit S.A. global market capitalization ranking is approximately 20345 as of 08/14/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.